Good morning, I'm Nikhil. I'm one of the third year internal medicine resident at Trinity Health Oakland Hospital, which is affiliated with Wayne State University School of Medicine. And here I am at ASH 2025 annual meeting presenting my research work on real world evidence of thrombotic events in patients with myelodysplastic syndrome who were treated with Luspertaracept versus erythropoietin stimulating agent. So basically Luspertaracept is an agent which is useful in maturation of the RBCs and we found it as one of the treatment options in patients with myelodysplastic syndrome. But previously before its approval to myelodysplastic syndrome, we know that it was approved for beta thalassemia patients. And there is a signal of increased risk of thrombotic events in patients treated with in that trial that made us and that prompted us to initiate this real world study in patients with myelodysplastic syndrome to look for if there is any signal for any more thrombotic events compared to the erythropoietin stimulating agents which are used to treat in patients with MDS. So we divided our study into primary and secondary outcome. The primary outcome was the composite venous thromboembolic events and the secondary outcomes were deep venous thrombosis and pulmonary embolism and also arterial thrombotic events like stroke and myocardial infarction. And we leveraged using Trinitix which is a population level data set which collects electronic health records of more than 130 healthcare institutions to get our analysis done. And on a propensity score matching of 1688 patients treated with Luspertaracept and 1688 treated with erythropoietin stimulating agents. We did not find any increased risk of composite venous thromboembolic events in patients with treated with Luspertaracept versus erythropoietin stimulating agents. Similarly, the trend was similar in other rest of the secondary outcomes like DVT, pulmonary embolism, stroke and myocardial infarction, although it did not reach statistical significance. So for real world patients what does this mean is our study bill is giving a signal that the drug is safe from thrombotic point of view compared to erythropoietin stimulating agents. And in future we would like to work more demonstrating the cardiovascular safety of the drug especially when we noted that the number of events like stroke and myocardial infarction are definitely less. We will work more on this to demonstrate if there is any safety signal from cardiovascular point of view which might even provide a benefit of mortality in the near future. That is our next line of work in this area. Thank you. If our videos have helped you in any way and you are able to please consider making a donation to help us continue this important work. Your gift will go three times as far when we reach $500,000 by the end of the year. Your contribution, big or small, makes a difference and we are deeply grateful for your support.
HealthTree • December 31, 2025